EGFR and non-small cell lung carcinoma: Furthermore, clinical trials have evaluated the combination of ipilimumab with the anti-EGFR TKI erlotinib in NSCLC [29], highlighting the need of more specific EGFR drugs with low frequencies of adverse side effects.